Cargando…

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer

Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the human trophoblast cell-surface antigen 2 to deliver SN-38 to cancer cells. In this study, we assessed the efficacy and safety of SG in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC). ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cheng, Shao-Xian, Chen, Qiu-Chi, Lin, Guo-He, Han, Yan-Hong, Wang, Bi-Cheng, Dai, Yi, Zhao, Yan-Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article: Systematic Review and Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378904/ https://www.ncbi.nlm.nih.gov/pubmed/37505137 http://dx.doi.org/10.1097/MD.0000000000034486

Ejemplares similares

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Sacituzumab govitecan in triple-negative breast cancer
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
por: Xie, Jiao, et al.
Publicado: (2023)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

Sacituzumab govitecan: ascending the treatment algorithm in triple negative breast cancer
por: Rozenblit, Mariya, et al.
Publicado: (2022)

Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
por: Chen, Jigang, et al.
Publicado: (2021)

Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
por: Lang, Yitian, et al.
Publicado: (2023)

Sacituzumab Govitecan: First Approval
por: Syed, Yahiya Y.
Publicado: (2020)

Sacituzumab govitecan for breast cancer
Publicado: (2022)

Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer
por: Nardin, Simone, et al.
Publicado: (2023)

The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer
por: Michaleas, S., et al.
Publicado: (2022)

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
por: Rugo, Hope S., et al.
Publicado: (2022)

Predictive biomarkers for sacituzumab govitecan efficacy in Trop-2-expressing triple-negative breast cancer
por: Cardillo, Thomas M., et al.
Publicado: (2020)

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
por: Carey, Lisa A., et al.
Publicado: (2022)

Neutropenic Enterocolitis: A Rare Complication of Sacituzumab Govitecan
por: Prescott, Adam Ethan, et al.
Publicado: (2022)

Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm
por: Olivier, Timothee, et al.
Publicado: (2021)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer
por: O’Shaughnessy, Joyce, et al.
Publicado: (2022)

Cost-effectiveness of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Shi, Demin, et al.
Publicado: (2023)

Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
por: Lopez, Salvatore, et al.
Publicado: (2020)

A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer
por: Ge, Long, et al.
Publicado: (2017)

Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
por: Fontes, Mariane S, et al.
Publicado: (2022)

The role of sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Avila, Jorge, et al.
Publicado: (2023)

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer
por: Coates, James T., et al.
Publicado: (2021)

Sacituzumab govitecan expands its therapeutic spectrum among breast cancer subtypes
por: Vranic, Semir
Publicado: (2023)

Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany
por: Reinisch, Mattea, et al.
Publicado: (2023)

The anti-Trop-2 antibody-drug conjugate Sacituzumab Govitecan—effectiveness, pitfalls and promises
por: Guerra, Emanuela, et al.
Publicado: (2022)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report
por: Han, Chanhee, et al.
Publicado: (2018)

Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
por: Webster, Emily M., et al.
Publicado: (2020)

A New Kid on the Block: Sacituzumab Govitecan for the Treatment of Breast Cancer and Other Solid Tumors
por: Pavone, Giuliana, et al.
Publicado: (2021)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
por: Liu, Wensheng, et al.
Publicado: (2023)

Efficacy and Safety of Platinum-Based Chemotherapy as First-Line Therapy for Metastatic Triple-Negative Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Fei, et al.
Publicado: (2021)

Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials
por: Shah, Chintan, et al.
Publicado: (2018)

Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p)
por: Liu, Jinghua, et al.
Publicado: (2017)

Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape
por: Adams, E., et al.
Publicado: (2021)

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release
por: Kopp, Anna, et al.
Publicado: (2023)

Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis
por: Xu, Linchun, et al.
Publicado: (2023)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

Meta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Wang, Ling, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7blrc5ek1huk1co5gtqssbfniu